02.06.2012 • News

Teva Chairman Buys 1 Million Shares of Drugmaker

The chairman of Teva Pharmaceutical Industries has purchased 1 million U.S.-listed shares of the world's largest generic drugmaker, the company said on Friday.

Board Chairman Phillip Frost bought the shares on Wednesday, the first day of trading on the New York Stock Exchange. Previously, the U.S.-listed shares of the Israeli company traded on Nasdaq.

Frost bought shares at prices ranging from $37.82 to $39.57, according to the company. The shares were up 0.5% at $39.38 on Friday, moving into positive territory after Teva announced Frost's purchase.

"This investment is simply a reflection of the strength of my conviction regarding Teva's bright future," Frost said in a company-released statement.

Teva, which has a market value of about $38 billion, recently installed Jeremy Levin, a former executive at Bristol-Myers Squibb, as its new chief executive.

 

 

Free Virtual Event

Batteries and Hydrogen: Competitors or Partners?
CHEManager Spotlight

Batteries and Hydrogen: Competitors or Partners?

17 September 2026 | Reserve your spot to learn where solid-state batteries and green hydrogen are headed—and how leading teams are turning them into scalable energy storage solutions.

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

most read